AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15033843 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Number of subjects: 878
Study 15033843 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 878
Study 11388882 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 0.038 mg/kg
Number of subjects: 24
Study 11388882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9253566 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% inspired oxygen
Number of subjects: 43
Study 9253566 — intervention group
Group type: COMPARATOR
Intervention: 25% inspired oxygen
Number of subjects: 43
Study 8276047 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1 mg) administered once daily for 8 days
Number of subjects: 0
Study 8276047 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered once daily for 8 days
Number of subjects: 0
Study 3821824 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mM cysteamine eyedrops
Number of subjects: 2
Study 3821824 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated eye)
Number of subjects: 2
Study 31727910 — intervention group
Group type: EXPERIMENTAL
Intervention: Alanine transaminase (ALT)
Number of subjects: 3458
Study 31727910 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkaline phosphatase (ALP)
Number of subjects: 3458
Study 31727910 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization (MR) for ALT
Number of subjects: 3458
Study 31727910 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization (MR) for ALP and GGT
Number of subjects: 3458
Study 28877165 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised water exercise twice a week for 12 weeks
Number of subjects: 516
Study 28877165 — intervention group
Group type: COMPARATOR
Intervention: Standard prenatal care
Number of subjects: 516
Study 28877165 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised water exercise
Number of subjects: 516
Study 25543679 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth ultrasonic subgingival debridement followed by Er:YAG laser application
Number of subjects: 40
Study 25543679 — intervention group
Group type: COMPARATOR
Intervention: Two sessions of ultrasonic debridement
Number of subjects: 40
Study 22819247 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed mode stimulation (alternating cathodic and anodic)
Number of subjects: 11
Study 22819247 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous anodic stimulation (full power)
Number of subjects: 11
Study 22819247 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation duration
Number of subjects: 11
Study 22819247 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrode location in lateral and anterior regions of DLPFC
Number of subjects: 11
Study 21889063 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional appliance
Number of subjects: 50
Study 21889063 — intervention group
Group type: COMPARATOR
Intervention: Self-ligating appliance
Number of subjects: 50
Study 21889063 — intervention group
Group type: EXPERIMENTAL
Intervention: Crowding
Number of subjects: 50
Study 20193310 — intervention group
Group type: EXPERIMENTAL
Intervention: CTN‐Vero‐RV
Number of subjects: 450
Study 20193310 — intervention group
Group type: COMPARATOR
Intervention: PVRV
Number of subjects: 450
Study 16462549 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual-based treatment for schizophrenia
Number of subjects: 0
Study 15201492 — intervention group
Group type: EXPERIMENTAL
Intervention: Kanji words reading
Number of subjects: 3
Study 15201492 — intervention group
Group type: EXPERIMENTAL
Intervention: Kana words reading
Number of subjects: 3
Study 15201492 — intervention group
Group type: EXPERIMENTAL
Intervention: Kana nonword reading
Number of subjects: 3
Study 15201492 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure alexia (ventromedial type)
Number of subjects: 3
Study 15201492 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure alexia (posterior type)
Number of subjects: 3
Study 15201492 — intervention group
Group type: EXPERIMENTAL
Intervention: Alexia with agraphia (orthographic alexia with agraphia)
Number of subjects: 3
Study 10903538 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultations with different mental health professionals
Number of subjects: 0
Study 10903538 — intervention group
Group type: EXPERIMENTAL
Intervention: In-patient days
Number of subjects: 0
Study 9291201 — intervention group
Group type: EXPERIMENTAL
Intervention: Candoxatrilat (100 mg i.v. bolus)
Number of subjects: 24
Study 9291201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7687206 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine (150-200 micrograms daily for 3 months)
Number of subjects: 12
Study 7687206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2942494 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg
Number of subjects: 9
Study 2942494 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2.5 mg
Number of subjects: 9
Study 2942494 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 30 mg
Number of subjects: 9
Study 2942494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 2942494 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg (after three repeated doses)
Number of subjects: 9
Study 30341124 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined physical and psychological intervention (BOOST programme)
Number of subjects: 402
Study 30341124 — intervention group
Group type: COMPARATOR
Intervention: Best practice advice (control)
Number of subjects: 402
Study 27411009 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 57
Study 27411009 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 57
Study 27411009 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (Vancomycin and Amoxicillin)
Number of subjects: 57
Study 27411009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 24720927 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 2331
Study 23168750 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 1 discharge
Number of subjects: 360
Study 23168750 — intervention group
Group type: COMPARATOR
Intervention: Day 2 discharge
Number of subjects: 360
Study 20350945 — intervention group
Group type: EXPERIMENTAL
Intervention: MGAWN1 (0.3, 1, 3, 10, or 30 mg/kg)
Number of subjects: 40
Study 20350945 — intervention group
Group type: EXPERIMENTAL
Intervention: MGAWN1 (3 mg/kg)
Number of subjects: 40
Study 20350945 — intervention group
Group type: EXPERIMENTAL
Intervention: MGAWN1
Number of subjects: 40
Study 20350945 — intervention group
Group type: EXPERIMENTAL
Intervention: MGAWN1 (30 mg/kg)
Number of subjects: 40
Study 20350945 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 40
Study 18034842 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (100 mg daily, given as equally divided doses)
Number of subjects: 576
Study 18034842 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone (30 mg daily, given as a single q.d. dose)
Number of subjects: 576
Study 16210717 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamins (B complex, C, and E)
Number of subjects: 1078
Study 16210717 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A plus beta-carotene
Number of subjects: 1078
Study 16210717 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamins that included vitamin A plus beta-carotene
Number of subjects: 1078
Study 16210717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1078
Study 11440493 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole alone at a dose of 75 mg t.i.d. orally for 8 weeks
Number of subjects: 30
Study 11440493 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole with exercise training at 60% of peak VO2 three times a week for 8 weeks
Number of subjects: 30
Study 11440493 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dipyridamole or exercise training)
Number of subjects: 30
Study 9699428 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior resin-bonded bridges (PRBBs)
Number of subjects: 0
Study 9699428 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement PRBBs
Number of subjects: 0
Study 7761963 — intervention group
Group type: EXPERIMENTAL
Intervention: Taleum (sodium cromoglycate) inhalation aerosol
Number of subjects: 34
Study 7761963 — intervention group
Group type: COMPARATOR
Intervention: Intal powder inhaled with the aid of a spinhaler
Number of subjects: 34
Study 3143016 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiotepa
Number of subjects: 149
Study 3143016 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C
Number of subjects: 149
Study 29371479 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab monotherapy
Number of subjects: 0
Study 29371479 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab in combination with lenalidomide and dexamethasone
Number of subjects: 0
Study 29371479 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab in combination with bortezomib and dexamethasone
Number of subjects: 0
Study 27265987 — intervention group
Group type: EXPERIMENTAL
Intervention: In-water recompression (IWR) for 82 minutes
Number of subjects: 0
Study 27265987 — intervention group
Group type: COMPARATOR
Intervention: Normobaric oxygen (NBO2) for 82 minutes
Number of subjects: 0
Study 24243397 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program (4 weeks of walking, balance and cognitive exercises, followed by 4 weeks of resistance exercise performed twice weekly at 20-50% of 1RM)
Number of subjects: 18
Study 24243397 — intervention group
Group type: EXPERIMENTAL
Intervention: After 24 weeks of training cessation
Number of subjects: 18
Study 22537508 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga therapy
Number of subjects: 250
Study 22537508 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic exercises
Number of subjects: 250
Study 20027105 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg rolofylline administered by intravenous infusion over 2 hours
Number of subjects: 0
Study 20027105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20027105 — intervention group
Group type: COMPARATOR
Intervention: Oral moxifloxacin
Number of subjects: 0
Study 18605129 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic relationship measures (working alliance, interpersonal behavior, narrative coherency) in early sessions
Number of subjects: 48
Study 15964408 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil 3 g daily (n = 22)
Number of subjects: 166
Study 15964408 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil 2 g daily (n = 94)
Number of subjects: 166
Study 15964408 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil 3 g daily (n = 21)
Number of subjects: 166
Study 15964408 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil 2 g daily (n = 29)
Number of subjects: 166
Study 11728846 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance medication
Number of subjects: 363
Study 11728846 — intervention group
Group type: EXPERIMENTAL
Intervention: Prodrome-based intervention
Number of subjects: 363
Study 11728846 — intervention group
Group type: COMPARATOR
Intervention: Crisis intervention
Number of subjects: 363
Study 11728846 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent treatment
Number of subjects: 363
Study 11728846 — intervention group
Group type: EXPERIMENTAL
Intervention: Prodrome-based intermittent intervention
Number of subjects: 363
Study 10802777 — intervention group
Group type: EXPERIMENTAL
Intervention: linomide (roquinimex)
Number of subjects: 811
Study 8625684 — intervention group
Group type: EXPERIMENTAL
Intervention: MV+PEEP, hypervolemia
Number of subjects: 21
Study 8625684 — intervention group
Group type: EXPERIMENTAL
Intervention: MV+PEEP, normovolemia
Number of subjects: 21
Study 8625684 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous breathing (SB), hypervolemia
Number of subjects: 21
Study 1471839 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous passive motion (CPM)
Number of subjects: 0
Study 1471839 — intervention group
Group type: COMPARATOR
Intervention: Control (immobilisation regimen)
Number of subjects: 0
Study 6368874 — intervention group
Group type: EXPERIMENTAL
Intervention: Desaminocysteine‐D‐arginine vasopressin (20 micrograms intranasally)
Number of subjects: 54
Study 6368874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 6368874 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 54
Study 30827470 — intervention group
Group type: EXPERIMENTAL
Intervention: IMT alongside comprehensive chest PT (PT+IMT)
Number of subjects: 36
Study 30827470 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive chest PT (PT)
Number of subjects: 36
Study 29589086 — intervention group
Group type: COMPARATOR
Intervention: Subchondral bone marrow concentrate injection (average of 6500 MSCs/mL)
Number of subjects: 30
Study 29589086 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 30
Study 27117455 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin bronchoscopy (UB)
Number of subjects: 40
Study 27117455 — intervention group
Group type: COMPARATOR
Intervention: Standard-size bronchoscopy (SB)
Number of subjects: 40
Study 24630419 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvimopan 12 mg (maximum: 15 inpatient doses)
Number of subjects: 277
Study 24630419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277
Study 22906179 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care intervention with low-intensity psychological treatments delivered by IAPT services.
Number of subjects: 450
Study 22906179 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 450
Study 22906179 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care intervention.
Number of subjects: 450
Study 19889809 — intervention group
Group type: EXPERIMENTAL
Intervention: High (n-3)LCPUFA beverage (1 g fat/kg body weight)
Number of subjects: 8
Study 19889809 — intervention group
Group type: EXPERIMENTAL
Intervention: Low (n-3)LCPUFA beverage (1 g fat/kg body weight)
Number of subjects: 8
Study 19889809 — intervention group
Group type: EXPERIMENTAL
Intervention: High (n-3)LCPUFA beverage
Number of subjects: 8
Study 19889809 — intervention group
Group type: COMPARATOR
Intervention: High and low (n-3)LCPUFA beverages
Number of subjects: 8
Study 16940036 — intervention group
Group type: EXPERIMENTAL
Intervention: Mono-protease inhibitor use
Number of subjects: 0
Study 16940036 — intervention group
Group type: COMPARATOR
Intervention: Dual-protease inhibitor use
Number of subjects: 0
Study 16319804 — intervention group
Group type: EXPERIMENTAL
Intervention: Humalog Mix25 (Mix25)
Number of subjects: 73
Study 16319804 — intervention group
Group type: COMPARATOR
Intervention: Maximum dose glibenclamide (control)
Number of subjects: 73
Study 11732662 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparins (LMWHs)
Number of subjects: 3500
Study 11732662 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 3500
Study 9426992 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 146
Study 9426992 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 146
Study 9426992 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 146
Study 3813951 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminocaproic acid (Amicar), 100 mg/kg every four hours, up to a maximum of 30 g/d for five days
Number of subjects: 34
Study 3813951 — intervention group
Group type: COMPARATOR
Intervention: Placebo for five days
Number of subjects: 34
Study 3813951 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminocaproic acid (Amicar)
Number of subjects: 34
Study 2665584 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) 1,500 micrograms/day
Number of subjects: 43
Study 2665584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 31613965 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin during pregnancy
Number of subjects: 145
Study 31613965 — intervention group
Group type: COMPARATOR
Intervention: Placebo during pregnancy
Number of subjects: 145
Study 31613965 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS
Number of subjects: 145
Study 30969136 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Number of subjects: 0
Study 30969136 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 0
Study 28558864 — intervention group
Group type: EXPERIMENTAL
Intervention: APAP 6-20 cm H2O
Number of subjects: 56
Study 28558864 — intervention group
Group type: COMPARATOR
Intervention: CPAP at recommended pressure
Number of subjects: 56
Study 25990545 — intervention group
Group type: EXPERIMENTAL
Intervention: Achilles decompression and debridement augmented with FHL transfer
Number of subjects: 39
Study 25990545 — intervention group
Group type: COMPARATOR
Intervention: Achilles decompression and debridement alone (control group)
Number of subjects: 39
Study 23437093 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair descending exercise
Number of subjects: 20
Study 23437093 — intervention group
Group type: COMPARATOR
Intervention: Stair ascending exercise
Number of subjects: 20
Study 22198589 — intervention group
Group type: EXPERIMENTAL
Intervention: Human fetal striatal transplantation (HFST)
Number of subjects: 0
Study 19485597 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping and Promoting Strength program (CAPS; n = 20)
Number of subjects: 40
Study 19485597 — intervention group
Group type: COMPARATOR
Intervention: Wait list control condition (WL; n = 20)
Number of subjects: 40
Study 19485597 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping and Promoting Strength program (CAPS)
Number of subjects: 40
Study 19485597 — intervention group
Group type: COMPARATOR
Intervention: Wait list control condition (WL)
Number of subjects: 40
Study 17046384 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanaproget 0.1 mg
Number of subjects: 8
Study 17046384 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanaproget 0.3 mg
Number of subjects: 8
Study 17046384 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanaproget 1 mg
Number of subjects: 8
Study 17046384 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanaproget 3 mg
Number of subjects: 8
Study 17046384 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanaproget 7 mg
Number of subjects: 8
Study 17046384 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanaproget 15 mg
Number of subjects: 8
Study 17046384 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal with tanaproget
Number of subjects: 8
Study 17046384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 14685868 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful contractions with 6% hypertonic saline injection
Number of subjects: 10
Study 14685868 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no pain)
Number of subjects: 10
Study 11502234 — intervention group
Group type: EXPERIMENTAL
Intervention: Stearic acid-rich meal
Number of subjects: 6
Study 11502234 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleic acid-rich meal
Number of subjects: 6
Study 11502234 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleic acid-rich meal
Number of subjects: 6
Study 9362186 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme supplementation
Number of subjects: 6
Study 9362186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8487073 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (55 Gy over a total of 6 1/2 to 7 weeks)
Number of subjects: 60
Study 8487073 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy plus CCNU (100 mg/sq m every 6 weeks)
Number of subjects: 60
Study 8487073 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 2963742 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-human atrial natriuretic polypeptide (alpha-hANP) infusion
Number of subjects: 10
Study 2963742 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 10
Study 31249394 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine protein:creatinine ratio (UPCR)
Number of subjects: 154
Study 31249394 — intervention group
Group type: EXPERIMENTAL
Intervention: UPCR cut-off value of 2.4
Number of subjects: 154
Study 31249394 — intervention group
Group type: COMPARATOR
Intervention: 24-hour urine protein
Number of subjects: 154
Study 28165608 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucoma personal record
Number of subjects: 122
Study 28165608 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical care (Control)
Number of subjects: 122
Study 26714488 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 60
Study 26714488 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 60
Study 26714488 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 60
Study 26714488 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 60
Study 26714488 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 60
Study 26714488 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 23730858 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology treatment for 1 week in three sessions following haemodialysis, each session lasting approximately 30 minutes
Number of subjects: 80
Study 23730858 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reflexology treatment)
Number of subjects: 80
Study 21262048 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weekly home visits focused on improving caregiver sensitivity
Number of subjects: 67
Study 21262048 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 67
Study 19793860 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and folic acid (IFA; 60 mg ferrous fumarate and 400 microg folic acid)
Number of subjects: 272